InMode (NASDAQ:INMD - Get Free Report) issued an update on its FY24 earnings guidance on Thursday morning. The company provided EPS guidance of $2.01-2.05 for the period, compared to the consensus EPS estimate of $2.49. The company issued revenue guidance of $485-495 million, compared to the consensus revenue estimate of $491.89 million.
InMode Price Performance
Shares of NASDAQ INMD traded up $0.12 during mid-day trading on Thursday, reaching $17.36. 2,641,998 shares of the company traded hands, compared to its average volume of 1,567,620. InMode has a fifty-two week low of $16.72 and a fifty-two week high of $48.25. The firm has a market cap of $1.46 billion, a PE ratio of 7.47 and a beta of 2.20. The stock has a fifty day simple moving average of $20.06 and a 200-day simple moving average of $21.40.
InMode (NASDAQ:INMD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 13th. The healthcare company reported $0.71 EPS for the quarter, beating analysts' consensus estimates of $0.66 by $0.05. InMode had a net margin of 40.22% and a return on equity of 29.80%. The business had revenue of $126.80 million for the quarter, compared to analyst estimates of $124.77 million. During the same quarter last year, the business earned $0.69 earnings per share. The business's revenue for the quarter was down 5.1% on a year-over-year basis. As a group, analysts predict that InMode will post 2.04 EPS for the current fiscal year.
Analyst Ratings Changes
A number of analysts recently weighed in on INMD shares. Needham & Company LLC restated a hold rating on shares of InMode in a report on Tuesday, April 9th. Barclays reduced their target price on shares of InMode from $34.00 to $33.00 and set an overweight rating for the company in a report on Friday, April 12th. Finally, UBS Group raised their target price on shares of InMode from $24.00 to $26.00 and gave the stock a neutral rating in a report on Wednesday, February 14th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of Hold and a consensus target price of $32.80.
Check Out Our Latest Research Report on InMode
About InMode
(
Get Free Report)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Featured Articles
Before you consider InMode, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.
While InMode currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
